Explain this page
Arphra AIPlain-English read on Pfizer Inc.’s valuationIncome statement
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|---|---|
| Revenue & profit | |||||||||
| Revenue | $81.29B | $100.33B | $59.55B | $63.63B | $62.58B | $61.74B | $59.2B | $54.7B | $53.02B |
| Cost of revenue | $34.41B | $38.24B | $29.21B | $21.78B | $18.57B | $23.76B | $22.59B | $21.14B | $20.55B |
| Gross profit | $46.88B | $62.09B | $30.34B | $41.85B | $44.01B | $39.11B | $37.53B | $34.22B | $32.19B |
| Gross margin | +57.67% | +61.89% | +50.95% | +65.77% | +70.33% | +63.35% | +63.39% | +62.57% | +60.71% |
| Operating | |||||||||
| Research & development | $13.83B | $11.43B | $10.58B | $10.74B | $11.98B | $10.88B | $10.43B | $9.52B | $9.63B |
| Selling, general & administrative | $12.25B | $13.12B | $14.47B | $14.73B | $13.35B | $14.19B | $13.22B | $12.41B | $12.29B |
| Total operating expenses | $26.08B | $24.54B | $25.05B | $25.36B | $28.58B | $26.1B | $24.64B | $23.93B | $23.15B |
| Operating income | $20.79B | $37.55B | $5.29B | $16.48B | $15.44B | $12.6B | $11.53B | $11.16B | $10.49B |
| Operating margin | +25.58% | +37.43% | +8.89% | +25.91% | +24.67% | +20.41% | +19.48% | +20.41% | +19.79% |
| EBITDA | $30.79B | $41.03B | $9.56B | $18.13B | $15.1B | $13.93B | $13.31B | $12.45B | $11.93B |
| EBIT | $25.6B | $35.97B | $3.27B | $11.11B | $10.19B | $8.18B | $7.69B | $7.17B | $7.1B |
| Below the line | |||||||||
| Interest expense | $1.29B | $1.24B | $2.21B | $3.09B | $2.67B | $2.61B | $2.57B | $2.28B | $2.34B |
| Interest income | $36M | $251M | $1.62B | $545M | $603M | $922.37M | $922.11M | $806.85M | $780.23M |
| Other income / expense | $3.52B | -$2.82B | -$4.23B | -$8.46B | -$7.92B | — | — | — | — |
| Pre-tax income | $24.31B | $34.73B | $1.06B | $8.02B | $7.52B | $5.45B | $5.21B | $4.82B | $4.67B |
| Income tax expense | $1.85B | $3.33B | -$1.11B | -$28M | -$266M | -$103.99M | -$102.16M | -$93.7M | -$91.99M |
| Earnings | |||||||||
| Net income | $22.15B | $31.37B | $2.13B | $8.02B | $7.77B | $5.74B | $5.71B | $5.23B | $5.2B |
| Net income · continuing ops | $22.46B | $31.4B | $2.17B | $8.05B | $7.79B | $5.92B | $5.56B | $5.34B | $5.16B |
| Net margin | +27.25% | +31.26% | +3.58% | +12.60% | +12.42% | +9.29% | +9.64% | +9.55% | +9.80% |
| EPS · basic | $3.95 | $5.59 | $0.38 | $1.42 | $1.36 | $2.94 | $2.85 | $2.46 | $2.35 |
| EPS · diluted | $3.88 | $5.47 | $0.37 | $1.41 | $1.36 | $2.96 | $2.83 | $2.43 | $2.31 |
| EPS · low estimate | — | — | — | — | — | $2.85 | $2.54 | $1.54 | $2.20 |
| EPS · high estimate | — | — | — | — | — | $3.04 | $3.00 | $2.77 | $2.42 |
| Shares · basic | 5.6B | 5.61B | 5.64B | 5.66B | 5.68B | 5.67B | 5.69B | 5.65B | 5.65B |
| Shares · diluted | 5.71B | 5.73B | 5.71B | 5.7B | 5.69B | 5.73B | 5.73B | 5.73B | 5.7B |
| Coverage | |||||||||
| Analysts (revenue) | — | — | — | — | — | 19 | 20 | 23 | 11 |
| Analysts (EPS) | — | — | — | — | — | 15 | 15 | 7 | 2 |
Coverage notes. Historical figures come’s as-reported income statements / balance sheets / cash flows in our data warehouse. Forecast columns (italicised, faint accent tint) carry vendor-supplied numbers where available (revenue + EPS consensus) and ratio-derived values for every other line. Margins / ratios are the trailing-3y average from history applied to the forecast revenue; values are clamped to enforce P&L identity (gross ≥ operating, EBITDA ≥ operating, net ≤ operating) and balance-sheet identity (assets = liabilities + equity by construction). Cash-flow FCF reconciles to OCF + CapEx. USD conversion uses the period-end close of the issuer's reported/USD pair from forex_prices_daily; share counts stay unconverted.
Financials
Full income statement, balance sheet, and cash-flow history is included with Pro.
Upgrade to Pro